Brii Biosciences Limited (HKG:2137)

Market Cap	1.23B
Revenue (ttm)	58.52M
Net Income (ttm)	-540.77M
Shares Out	719.27M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,075,500
Average Volume	3,973,850
Open	1.720
Previous Close	1.710
Day's Range	1.660 - 1.730
52-Week Range	0.800 - 3.090
Beta	1.48
RSI	41.75
Earnings Date	Aug 19, 2025

About Brii Biosciences

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 98
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2137

Financial Performance

In 2024, Brii Biosciences's revenue was 54.99 million, a decrease of -2.36% compared to the previous year's 56.32 million. Losses were -508.16 million, 190.7% more than in 2023.

Financial numbers in CNY